(ANSA) - TRIESTE, 25 MAR - Elettra Sincrotrone Trieste undertakes to give top priority to experiments useful for identifying drugs, vaccines and diagnostic methods capable of dealing with the Covid-19 pandemic as soon as possible. The Elettra synchrotron light source and the Fermi free-electron laser, with their experimental stations, will, therefore, be made available to researchers from all over the world who will have the opportunity to request access to the lines of light with a priority procedure to make measurements remotely, therefore, without having to physically move to the Elettra laboratories. These measurements could be useful to shed light on the molecular components of the SARS-CoV-2 virus, the agent responsible for the infection. The call is highlighted on the home page of the website www.elettra.eu. The research will take place by sending samples that Elettra researchers will measure using sophisticated techniques. Further experiments, aimed at studying the effectiveness of some drugs such as chloroquine, will be conducted at the 'Fermi' light source. Finally, serological diagnostic devices will be developed in the Nanotechnology Laboratory of Elettra Sincrotrone Trieste in collaboration with the SISSA Neurobiology laboratories. The aim of the research is the possibility of using these devices for epidemiological monitoring and the identification of newly infected people. "All the activities will be carried out without incurring risks - underlined professor Alfonso Franciosi, President and CEO of Elettra Sincrotrone Trieste - as the molecular components of the virus that can be studied are proteins, macromolecular complexes or small non-pathogenic chemical compounds, but useful to quickly identify new therapies or new methods of protection from the virus."(ANSA).